Salute e Benessere
Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®
Neuraxpharm has acquired these products in most markets outside the US^. Provigil's main market is Europe , with significant sales in France , Spain and Italy . Nuvigil is present in international markets with significant sales in Australia and Mexico . Both Provigil and Nuvigil are orally administered CNS stimulants indicated to improve wakefulness and reduce Excessive Daytime Sleepiness (EDS) in adult patients with narcolepsy, both with and without cataplexy.
This acquisition is in line with Neuraxpharm's strategy to grow strong CNS brands and bring them to increasing numbers of patients worldwide. It will enable entry into new territories such as Australia , where Neuraxpharm also plans to launch first-in-class multiple sclerosis treatment ublituximab (BRIUMVI®), and will furthermore reinforce Neuraxpharm's presence in Mexico , where the Company established an office in 2023.
The transaction follows the acquisition from Sanofi of two established product portfolios in 2023 and the securing of a landmark partnership with TG Therapeutics also in 2023 to commercialise ublituximab outside the US*. In 2020, Neuraxpharm acquired market-leading child epilepsy treatment Buccolam® (oromucosal midazolam) from Takeda, and in September last year Neuraxpharm received a positive CHMP opinion from the European Medicine Agency to extend Buccolam's indication to include the treatment of epilepsy in adults.
"
No financial details of the transaction have been disclosed.
^ Republic of Korea, Japan ,
Thailand and the United States are not included in this acquisition.
* Territories outside the United States ,
Canada , Mexico , and excluding certain Asian countries previously partnered.
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 35 years.
Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships, and acquisitions.
The company has c.1,000 employees and develops and commercializes CNS products through a direct presence in more than 20 countries in Europe , two in Latin America , one in the Middle East , and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira.
Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain .
For more information, please visit https://www.neuraxpharm.com
View original content: https://www.prnewswire.co.uk/news-releases/neuraxpharm-to-further-grow-branded-business-with-the-acquisition-of-two-leading-narcolepsy-treatments-provigil-and-nuvigil-302343298.html